Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
9
¥100 million (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥20,031 million
Operating profit¥807 million
Ordinary income¥1,574 million
Net income¥1,215 million profit attributable to owners of the parent
Gross Profit Margin34.6%
Operating profit margin4.0%
Selling, general and administrative expenses¥6,130 million
Results for the three months of the current quarterFor 26Q1, revenue was ¥20.03 billion, operating profit was ¥800 million, and quarterly net income attributable to owners of the parent was ¥1.21 billion
Full-year earnings forecast
Net Sales
¥85,000 million
Gross profit
¥27,700 million
Operating profit
¥3,300 million
Ordinary income
¥4,600 million
Profit attributable to owners of the parent
¥6,500 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net SalesB&P +¥424 million, Healthcare +¥912 million, Creative Work -¥56 million, V&S +¥993 million, Amusement +¥790 million, Other -¥370 million, total +¥2.273 billion
Operating profitForeign-exchange impact +¥359 million, impact of higher revenue +¥460 million, gross margin impact -¥56 million, decrease in selling, general and administrative expenses +¥141 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Average annual USD exchange rate¥160.00
Average annual EUR exchange rate¥175.00
Operating profit foreign-exchange sensitivityA ¥1 depreciation against the US dollar: -¥80 million; a ¥1 depreciation against the euro: +¥100 million
New initiatives
- Launch of the PX3150 monitor dedicated to displaying pathology images
- Introduction of what the company describes as the world's first standard seven-year warranty for monitors, including eligible products scheduled for launch this autumn
- Expansion of the share buyback authorization to 5.5 million shares and ¥17 billion
Segment results
B&P
Net Sales¥3.33 billion, 114.6% year on year
Healthcare
Net Sales¥8.40 billion, 112.2% year on year
Creative Work
Net Sales¥1.09 billion, 95.1% year on year
V&S
Net Sales¥3.59 billion, 138.2% year on year
Amusement
Net Sales¥2.10 billion, 160.3% year on year
Other
Net Sales¥1.50 billion, down year on year
Medium-term management plan targets
The next medium-term management plan is scheduled to be announced during 2026. Specific target figures: not disclosedFinancial targets
ROA 2.3%, ROE 5.6% (listed in the full-year outlook section; it is not specified whether these are target or actual figures)Acquisition of treasury shares
Number of shares acquired5.5 million shares (maximum; 13.91% of total shares issued)
Acquisition price¥17 billion (maximum)
Acquisition period25 May 2026 to 24 May 2027
Method of acquisitionMarket purchases on the Tokyo Stock Exchange, including ToSTNeT-3
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥20,031 million |
| Operating profit | ¥807 million |
| Ordinary income | ¥1,574 million |
| Net income | ¥1,215 million (profit attributable to owners of the parent) |
| Gross Profit Margin | 34.6% |
| Operating profit margin | 4.0% |
| Selling, general and administrative expenses | ¥6,130 million |
| Results for the three months of the current quarter | For 26Q1, revenue was ¥20.03 billion, operating profit was ¥800 million, and quarterly net income attributable to owners of the parent was ¥1.21 billion |
| Full-year earnings forecast | Net Sales ¥85,000 million / Gross profit ¥27,700 million / Operating profit ¥3,300 million / Ordinary income ¥4,600 million / Profit attributable to owners of the parent ¥6,500 million |
| Segment results | B&P Net Sales ¥3.33 billion, 114.6% year on year / Healthcare Net Sales ¥8.40 billion, 112.2% year on year / Creative Work Net Sales ¥1.09 billion, 95.1% year on year / V&S Net Sales ¥3.59 billion, 138.2% year on year / Amusement Net Sales ¥2.10 billion, 160.3% year on year / Other Net Sales ¥1.50 billion, down year on year |
| Breakdown of Factors Affecting the Change | Net Sales B&P +¥424 million, Healthcare +¥912 million, Creative Work -¥56 million, V&S +¥993 million, Amusement +¥790 million, Other -¥370 million, total +¥2.273 billion / Operating profit Foreign-exchange impact +¥359 million, impact of higher revenue +¥460 million, gross margin impact -¥56 million, decrease in selling, general and administrative expenses +¥141 million |
| Assumptions Underlying the Business Outlook | Average annual USD exchange rate ¥160.00 / Average annual EUR exchange rate ¥175.00 / Operating profit foreign-exchange sensitivity A ¥1 depreciation against the US dollar: -¥80 million; a ¥1 depreciation against the euro: +¥100 million |
| Medium-term management plan targets | The next medium-term management plan is scheduled to be announced during 2026. Specific target figures: not disclosed |
| Financial targets | ROA 2.3%, ROE 5.6% (listed in the full-year outlook section; it is not specified whether these are target or actual figures) |
| Acquisition of treasury shares | Number of shares acquired 5.5 million shares (maximum; 13.91% of total shares issued) / Acquisition price ¥17 billion (maximum) / Acquisition period 25 May 2026 to 24 May 2027 / Method of acquisition Market purchases on the Tokyo Stock Exchange, including ToSTNeT-3 |
| New initiatives | Launch of the PX3150 monitor dedicated to displaying pathology images, Introduction of what the company describes as the world's first standard seven-year warranty for monitors, including eligible products scheduled for launch this autumn, Expansion of the share buyback authorization to 5.5 million shares and ¥17 billion |
Items this document does not state (13)
Progress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the accumulation of sales projects and solid overseas sales in the healthcare and V&S markets. Operating profit increased due to the effect of higher revenue, foreign-exchange gains from the weaker yen and stronger euro, fixed-cost reductions from the restructuring and streamlining of the organizational structure in Europe, and the absence of one-time expenses related to the new technology building recorded in the same quarter of the previous fiscal year. The company cited responding to changes in net assets caused by fluctuations in the prices of investment securities, as well as improving capital efficiency and total shareholder return, as reasons for expanding the share buyback authorization.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.